BCL2 and neoplasm: Compared to the treatment with the diluent DMSO (Fig. 3B) and treatments indicated in Fig. 3C, navitoclax (BCL-2/BCL-xl inhibitor) as well as the combinations navitoclax + everolimus (mTORC1 inhibitor) and quisinostat (HDAC inhibitor) + flavopiridol (CDK inhibitor) resulted in a significant and marked reduction in tumor burden, while everolimus + sotrastaurin (PKC inhibitor) resulted in a significant but moderate reduction (Fig. 3D, E).